Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 138

Similar articles for PubMed (Select 23599155)

1.
2.

Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing.

Djordjevic B, Hennessy BT, Li J, Barkoh BA, Luthra R, Mills GB, Broaddus RR.

Mod Pathol. 2012 May;25(5):699-708. doi: 10.1038/modpathol.2011.208. Epub 2012 Feb 3.

3.

Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset.

Garg K, Shih K, Barakat R, Zhou Q, Iasonos A, Soslow RA.

Am J Surg Pathol. 2009 Dec;33(12):1869-77. doi: 10.1097/PAS.0b013e3181bc9866.

PMID:
19898223
4.

Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities.

Garg K, Leitao MM Jr, Kauff ND, Hansen J, Kosarin K, Shia J, Soslow RA.

Am J Surg Pathol. 2009 Jun;33(6):925-33. doi: 10.1097/PAS.0b013e318197a046.

PMID:
19238076
5.

Utility of MLH1 methylation analysis in the clinical evaluation of Lynch Syndrome in women with endometrial cancer.

Bruegl AS, Djordjevic B, Urbauer DL, Westin SN, Soliman PT, Lu KH, Luthra R, Broaddus RR.

Curr Pharm Des. 2014;20(11):1655-63.

6.

Molecular, pathologic, and clinical features of early-onset endometrial cancer: identifying presumptive Lynch syndrome patients.

Walsh MD, Cummings MC, Buchanan DD, Dambacher WM, Arnold S, McKeone D, Byrnes R, Barker MA, Leggett BA, Gattas M, Jass JR, Spurdle AB, Young J, Obermair A.

Clin Cancer Res. 2008 Mar 15;14(6):1692-700. doi: 10.1158/1078-0432.CCR-07-1849. Epub 2008 Feb 29.

7.

Molecular characterization of endometrial cancer: a correlative study assessing microsatellite instability, MLH1 hypermethylation, DNA mismatch repair protein expression, and PTEN, PIK3CA, KRAS, and BRAF mutation analysis.

Peterson LM, Kipp BR, Halling KC, Kerr SE, Smith DI, Distad TJ, Clayton AC, Medeiros F.

Int J Gynecol Pathol. 2012 May;31(3):195-205. doi: 10.1097/PGP.0b013e318231fc51.

PMID:
22498935
8.

Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: a potential target treatment.

Peiró G, Peiró FM, Ortiz-Martínez F, Planelles M, Sánchez-Tejada L, Alenda C, Ceballos S, Sánchez-Payá J, Laforga JB.

Hum Pathol. 2013 Feb;44(2):218-25. doi: 10.1016/j.humpath.2012.05.008. Epub 2012 Sep 3.

PMID:
22955108
9.

Lynch Syndrome in patients with clear cell and endometrioid cancers of the ovary.

Vierkoetter KR, Ayabe AR, VanDrunen M, Ahn HJ, Shimizu DM, Terada KY.

Gynecol Oncol. 2014 Oct;135(1):81-4. doi: 10.1016/j.ygyno.2014.07.100. Epub 2014 Aug 2.

PMID:
25093288
10.

A two-antibody mismatch repair protein immunohistochemistry screening approach for colorectal carcinomas, skin sebaceous tumors, and gynecologic tract carcinomas.

Mojtahed A, Schrijver I, Ford JM, Longacre TA, Pai RK.

Mod Pathol. 2011 Jul;24(7):1004-14. doi: 10.1038/modpathol.2011.55. Epub 2011 Apr 15.

11.

MMR deficiency is common in high-grade endometrioid carcinomas and is associated with an unfavorable outcome.

Nelson GS, Pink A, Lee S, Han G, Morris D, Ogilvie T, Duggan MA, Köbel M.

Gynecol Oncol. 2013 Nov;131(2):309-14. doi: 10.1016/j.ygyno.2013.08.003. Epub 2013 Aug 11.

PMID:
23938375
12.

Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.

Soslow RA, Wethington SL, Cesari M, Chiappetta D, Olvera N, Shia J, Levine DA.

Am J Surg Pathol. 2012 Dec;36(12):1771-81. doi: 10.1097/PAS.0b013e318273591a.

PMID:
23154767
13.

Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome.

Rabban JT, Calkins SM, Karnezis AN, Grenert JP, Blanco A, Crawford B, Chen LM.

Am J Surg Pathol. 2014 Jun;38(6):793-800. doi: 10.1097/PAS.0000000000000177.

PMID:
24503759
14.

Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer.

Bosse T, ter Haar NT, Seeber LM, v Diest PJ, Hes FJ, Vasen HF, Nout RA, Creutzberg CL, Morreau H, Smit VT.

Mod Pathol. 2013 Nov;26(11):1525-35. doi: 10.1038/modpathol.2013.96. Epub 2013 May 24.

15.

[The first molecular analysis of a Hungarian HNPCC family: a novel MSH2 germline mutation].

Czakó L, Tiszlavicz L, Takács R, Baradnay G, Lonovics J, Cserni G, Závodná K, Bartosova Z.

Orv Hetil. 2005 May 15;146(20):1009-16. Hungarian.

PMID:
15945244
16.

Causes and consequences of microsatellite instability in endometrial carcinoma.

Gurin CC, Federici MG, Kang L, Boyd J.

Cancer Res. 1999 Jan 15;59(2):462-6.

17.

Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing.

Buchanan DD, Tan YY, Walsh MD, Clendenning M, Metcalf AM, Ferguson K, Arnold ST, Thompson BA, Lose FA, Parsons MT, Walters RJ, Pearson SA, Cummings M, Oehler MK, Blomfield PB, Quinn MA, Kirk JA, Stewart CJ, Obermair A, Young JP, Webb PM, Spurdle AB.

J Clin Oncol. 2014 Jan 10;32(2):90-100. doi: 10.1200/JCO.2013.51.2129. Epub 2013 Dec 9.

18.
19.

ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas.

Allo G, Bernardini MQ, Wu RC, Shih IeM, Kalloger S, Pollett A, Gilks CB, Clarke BA.

Mod Pathol. 2014 Feb;27(2):255-61. doi: 10.1038/modpathol.2013.144. Epub 2013 Jul 26.

20.

Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer ≤ 70 years.

Leenen CH, van Lier MG, van Doorn HC, van Leerdam ME, Kooi SG, de Waard J, Hoedemaeker RF, van den Ouweland AM, Hulspas SM, Dubbink HJ, Kuipers EJ, Wagner A, Dinjens WN, Steyerberg EW.

Gynecol Oncol. 2012 May;125(2):414-20. doi: 10.1016/j.ygyno.2012.01.049. Epub 2012 Feb 1.

PMID:
22306203
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk